reason report
new bigger diversifi compani massiv
bottom line last friday afternoon complet acquisit
allergan follow receipt regulatori approv govern
author approv irish high court detail pro-
forma guidanc combin compani provid
press releas manag suggest total revenu
combin compani full-year revenu allergan
expect reach ex-humira stand-alone
revenu guidanc manag seem assum
high single-digit declin allergan revenu
updat svb leerink forma model point steadi growth
flat pro-rat allergan
 combin pro forma model partial
expect revenu combin compani partial allergan
reach y/i q/q full-year revenu
forecast y/i despit temporari weak
allergan aesthet busi anticip top line
combin compani continu grow reach
peak essenti flat assum
addit pipelin contribut current market product
increment indic
model incorpor previous disclos annual
oper expens synergi expect signific
portion expens synergi compar prior model
achiev save estim free
cash flow combin compani
full-year expect continu grow
rate per year free cash flow per
year anticip next year combin compani
abl bring leverag net debt/ebitda
end maintain dividend pay-out ratio least
current level expect new go pro forma ep
year compar
previous remain posit overal capit alloc
strategi believ combin compani attract risk-
reward profil large-cap biopharma peer
close histor acquisit humira
product sale gross profit compar
revenu gross profit last year moreov combin
compani inform svb leerink llc research
revenu mm dilut ep includ option expens present
averag dcf price-to-earnings p/sale
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
compani estim nearli free cash flow year
next year annual free cash flow yield today enterpris
valu basi investor see full enterpris valu
recov free cash flow next year notwithstand much
alloc debt reduct combin compani
revenu multipl sale investor like
see earli robust synergi trend stabl slightli grow
combin compani revenu year realiz
combin compani stock unsustain cheap current rang
svb leerink price target increas base increas
expect revenu ep new next year
stabl growth outlook greater diversif combin
compani increas price target
reiter outperform rate compani stock expect
stock trade posit deal anticip good news
pivot trial new indic skyrizi rinvoq longer
term believ still need acquisit particularli
oncolog area expect manag spend year
focus integr cost effici portfolio priorit
price target per share stock rate outperform
establish independ pharmaceut compani transit new
phase term scale oper effici acquisit allergan close may
allergan bring new revenu market categori outsid
current product portfolio allergan aesthet busi one endur franchis
industri unlik advers affect mani risk face tradit
necessarili fan consolid sake see bring
disciplin decis allergan portfolio confid maxim
valu allergan aesthet busi cash flow without disrupt
effect busi unit innov cultur commerci effect ad
allergan dilut exposur humira posit view
offer compani signific opportun oper effici
synergi alreadi disclos face mani risk humira franchis rebat
reform patent challeng biosimilar pathway chang patent reform product cash
flow seem rel secur risk seem price investor
expect beyond two cornerston hematolog busi grow
strongli sever year least emerg combin neurosci portfolio
gener signific revenu posit cash flow earli import
pipelin program combin compani come skyrizi venclexta imbruvica
new indic signific increment opportun probabl allergan
neurolog migrain psychiatri schizophrenia program boost back
indic compani long sinc abandon see combin compani
deliv mid-singl digit revenu growth high-singl digit ep growth
price target base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar larg biopharmaceut compani price sale multipl
large-cap peer compani stock discount cash flow dcf appli peer ep
revenu multipl use averag large-cap larg molecul therapeut compani
mid-term growth tail risk averag consensu ep
multipl appli current ep estim give valu
use revenu multipl similar compani consensu sale
nv san fp gsk ln appli revenu estim
give valu lastli dcf valuat given wacc
termin cash flow growth rate begin humira biosimilar entri give
present valu averag three method current price target
risk view outlook valuat includ major chang price
outlook reimburs coverag label competit posit humira compani
main product risk includ commerci develop disappoint compani
follow-on program inflammatori diseas imbruvica venclexta expand
hematolog malign well competit posit compani next-
gener hcv therapi also compani remain highli lever commit grow
dividend reduct forecast ebitda due neg busi trend would place
compani capit alloc strategi dividend growth risk opportun upsid
expect includ stronger-than-expect price volum share humira
emerg tangibl demand underappreci element compani early-
mid-stag pipelin asset potenti label expans opportun late-stag opportun
type event
event trial detail
date known
up/down
expect
primari complet
brand
fda action bla launch expect
sbla submiss expect
primari complet
primari complet
sbla submiss expect
phase trial progress form ms
regulatori submiss cgvhd
phase readout ra
phase readout uc
phase readout ps
phase readout solid tumor
phase readout solid tumor
regulatori submiss ovarian breast
open label studi assess safety/toler
svb leerink llc equiti research compani file
sec gov compani websit present svbl analysi
phase ii data
phase data
phase ii data earli
phase ii data
phase ii data
phase ii data
phase data
phase data
phase ii data
phase ii data
phase ii data
bla file accept
decis
decis phase
phase data late
phase data
phase data
phase data
phase data
phase data
phase data
phase data
million
svb leerink llc research compani file
million
good sold
 total revenu
sg total revenu
svb leerink llc research compani file
analysi stock price svb leerink target
method price base current larg cap hc stock mid-term growth tail risk
ep multipl appli ep
svb leerink forma ep estim
method present valu base price sale multipl peer larg cap biopharma stock
nv sni gsk appli expect revenu
averag price sale larg cap biopharma multipl
impli market cap mm estimate sale
anticip share count mm
method leerink probabl adjust dcf adjust net wacc termin
sourc svb leerink llc estim compani file factset
